Q-omics provides the consensus-scored TMEM269 profile across patient tissues and cancer cell-line models. TMEM269 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM269 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TMEM269 RNA expression shows 17,151 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KIRC, and ACC as cancer lineages where TMEM269 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM269 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM269 survival associations across molecular data types. TMEM269 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM269 RNA expression–survival associations across cancer types. High TMEM269 expression shows unfavorable associations in KIRP, ACC, KIRC and COAD, but favorable associations in SKCM and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM269 RNA expression.
This table summarizes TMEM269 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM269. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM269 shows higher tumor expression in KIRC, LIHC, HNSC, LUSC, CHOL and LUAD. The KIRC box plot shows higher TMEM269 RNA expression in tumor versus normal tissue (log2 FC = +0.087, t-test p < 0.001).
This table shows molecular features associated with TMEM269 in patient tissues and cancer cell lines. In patient samples, TMEM269 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM269 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
